Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) - Investment analysts at Brookline Capital Management issued their FY2029 earnings per share estimates for Intellia Therapeutics in a research note issued on Monday, January 6th. Brookline Capital Management analyst L. Cann expects that the company will earn $93.13 per share for the year. The consensus estimate for Intellia Therapeutics' current full-year earnings is ($5.12) per share.
Other analysts also recently issued research reports about the company. Citigroup cut their price target on Intellia Therapeutics from $25.00 to $19.00 and set a "neutral" rating on the stock in a research note on Friday, October 25th. Stifel Nicolaus cut their target price on Intellia Therapeutics from $80.00 to $64.00 and set a "buy" rating on the stock in a research note on Wednesday, September 11th. Oppenheimer lowered their price target on Intellia Therapeutics from $70.00 to $60.00 and set an "outperform" rating for the company in a research report on Monday, November 11th. William Blair reissued a "neutral" rating and set a $14.00 price objective on shares of Intellia Therapeutics in a research report on Monday, November 18th. Finally, Robert W. Baird decreased their target price on shares of Intellia Therapeutics from $24.00 to $18.00 and set a "neutral" rating for the company in a report on Friday, October 25th. One analyst has rated the stock with a sell rating, six have given a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Intellia Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $54.94.
Get Our Latest Report on Intellia Therapeutics
Intellia Therapeutics Trading Down 3.6 %
NTLA traded down $0.45 during midday trading on Wednesday, reaching $12.02. The company's stock had a trading volume of 1,892,446 shares, compared to its average volume of 2,490,008. The stock's 50-day moving average is $13.96 and its 200-day moving average is $19.20. Intellia Therapeutics has a 1 year low of $11.34 and a 1 year high of $34.87. The firm has a market capitalization of $1.22 billion, a price-to-earnings ratio of -2.21 and a beta of 1.83.
Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($1.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.37) by $0.03. The business had revenue of $9.10 million during the quarter, compared to the consensus estimate of $8.28 million. During the same quarter in the previous year, the business earned ($1.38) earnings per share. The firm's revenue was down 24.1% compared to the same quarter last year.
Institutional Trading of Intellia Therapeutics
Hedge funds and other institutional investors have recently bought and sold shares of the stock. EverSource Wealth Advisors LLC grew its stake in shares of Intellia Therapeutics by 763.5% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,753 shares of the company's stock valued at $39,000 after acquiring an additional 1,550 shares during the period. Eastern Bank bought a new position in shares of Intellia Therapeutics in the third quarter worth approximately $41,000. Values First Advisors Inc. purchased a new stake in shares of Intellia Therapeutics in the third quarter worth $54,000. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Intellia Therapeutics by 27.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,674 shares of the company's stock valued at $77,000 after purchasing an additional 794 shares during the period. Finally, KBC Group NV raised its position in shares of Intellia Therapeutics by 37.3% during the 3rd quarter. KBC Group NV now owns 3,753 shares of the company's stock valued at $77,000 after purchasing an additional 1,020 shares during the period. Hedge funds and other institutional investors own 88.77% of the company's stock.
Insider Buying and Selling at Intellia Therapeutics
In related news, CEO John M. Leonard sold 26,807 shares of the firm's stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $12.18, for a total value of $326,509.26. Following the transaction, the chief executive officer now directly owns 941,115 shares of the company's stock, valued at approximately $11,462,780.70. This trade represents a 2.77 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold a total of 28,735 shares of company stock worth $349,909 in the last three months. 3.20% of the stock is currently owned by company insiders.
Intellia Therapeutics Company Profile
(
Get Free Report)
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.
See Also
Before you consider Intellia Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intellia Therapeutics wasn't on the list.
While Intellia Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
